^
BIOMARKER:

NBN mutation

i
Other names: NBN, Nibrin, Nijmegen Breakage Syndrome 1 (Nibrin), Cell Cycle Regulatory Protein P95, NBS1, NBS, P95, P95 Protein Of The MRE11/RAD50 Complex, Nijmegen Breakage Syndrome Protein 1, AT-V1, AT-V2, ATV
Entrez ID:
Phase 2
Fudan University
Recruiting
Last update posted :
06/30/2022
Initiation :
09/14/2020
Primary completion :
11/20/2022
Completion :
12/28/2022
HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • RAD50 • CHEK1 • BARD1 • FANCF • FANCM • NBN • WRN • FANCD2 • FANCC
|
HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • BLM mutation • CHEK1 mutation • NBN mutation • FANCM mutation • CHEK1 expression
|
Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • pucotenlimab (HX008) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Sidney Kimmel Comprehensive Cancer Center at Jo...
Recruiting
Last update posted :
06/13/2022
Initiation :
09/10/2018
Primary completion :
12/01/2022
Completion :
05/01/2023
BRCA1 • BRCA2 • ATM • CHEK2 • FANCA • RAD51C • RAD51D • RAD50 • FANCF • FANCL • FANCI • FANCM • NBN • FANCD2 • FANCG • FANCB • FANCC
|
CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD50 mutation • FANCF mutation • NBN mutation • FANCG mutation • FANCI mutation • FANCM mutation
|
Rubraca (rucaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Shadia Jalal, MD
Recruiting
Last update posted :
05/24/2022
Initiation :
07/09/2019
Primary completion :
11/01/2023
Completion :
11/01/2024
BRCA1 • BRCA2 • ARID1A • CDK12 • RAD51 • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • RAD54L • BARD1 • NBN • GEN1
|
BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Assistance Publique - Hôpitaux de Paris
Not yet recruiting
Last update posted :
05/17/2022
Initiation :
10/01/2022
Primary completion :
11/01/2027
Completion :
11/01/2027
TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MSH6 • MLH1 • MSH2 • CDH1 • BRIP1 • CHEK2 • RAD51C • RAD51D • RAD50 • BARD1 • NBN • HOXB13
|
BRCA1 mutation • PTEN mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • MSH2 mutation • RAD50 mutation • BARD1 mutation • MRE11A mutation • BLM mutation • MLH3 mutation • NBN mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
HonorHealth Research Institute
Not yet recruiting
Last update posted :
05/12/2022
Initiation :
08/01/2022
Primary completion :
08/31/2025
Completion :
08/31/2026
BRCA1 • BRCA2 • PTEN • ARID1A • RAD51 • BRIP1 • CHEK2 • NBN • EMSY • CA 19-9
|
BRCA1 mutation • ATM mutation • PTEN mutation • PALB2 mutation • BRIP1 mutation • CHEK2 mutation • NBN mutation • RAD51 mutation
|
Zepzelca (lurbinectedin) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Academic and Community Cancer Research United
Recruiting
Last update posted :
05/09/2022
Initiation :
06/09/2020
Primary completion :
09/30/2022
Completion :
09/30/2024
BRCA1 • BRCA2 • PTEN • HRD • ARID1A • RAD51 • BRIP1 • CHEK2 • ATR • BRCA • NBN • EMSY
|
BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • ARID1A mutation • PALB2 mutation • BRIP1 mutation • CHEK2 mutation • BRCA mutation • NBN mutation • EMSY mutation • RAD51 mutation
|
Lynparza (olaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Asan Medical Center
Recruiting
Last update posted :
04/12/2022
Initiation :
04/01/2022
Primary completion :
10/30/2023
Completion :
10/30/2024
BRCA1 • BRCA2 • ATM • POLE • BAP1 • MSH6 • MLH1 • MSH2 • RAD51 • BRIP1 • CHEK2 • FANCA • RAD51C • BRCA • RAD51D • RAD50 • CHEK1 • BARD1 • XRCC2 • NBN • FANCD2 • GEN1
|
ATM mutation • BAP1 mutation • BRIP1 mutation • CHEK2 mutation • FANCA mutation • RAD50 mutation • BARD1 mutation • BLM mutation • NBN mutation
|
Lynparza (olaparib) • Imfinzi (durvalumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Massachusetts General Hospital
Completed
Last update posted :
04/08/2022
Initiation :
01/08/2019
Primary completion :
06/01/2020
Completion :
07/08/2020
BRCA1 • BRCA2 • MYC • ATM • ARID1A • CCNE1 • CDK12 • FBXW7 • ATRX • RAD51B • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • BARD1 • FANCF • FANCM • NBN • FANCC
|
BRCA2 mutation • BRCA1 mutation • ATM mutation • ARID1A mutation • MYC amplification • CDK12 mutation • CCNE1 amplification • ATRX mutation • FBXW7 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation
|
berzosertib (M6620) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Clovis Oncology, Inc.
Active, not recruiting
Last update posted :
03/28/2022
Initiation :
11/21/2019
Primary completion :
05/01/2022
Completion :
06/01/2022
BRCA1 • BRCA2 • RAD51 • RAD51B • BRIP1 • FANCA • RAD51C • RAD51D • BARD1 • NBN
|
BRCA1 mutation • PALB2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • NBN mutation • FANCA deletion • RAD51 mutation
|
Rubraca (rucaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2b
University of Kansas Medical Center
Recruiting
Last update posted :
02/15/2022
Initiation :
12/14/2021
Primary completion :
08/01/2025
Completion :
01/31/2026
BRCA1 • BRCA2 • PTEN • STK11 • NF1 • CDH1 • CHEK2 • NBN
|
PTEN mutation • PALB2 mutation • CHEK2 mutation • NBN mutation
|
Duavee (conjugated estrogens / bazedoxifene) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Massachusetts General Hospital
Recruiting
Last update posted :
01/31/2022
Initiation :
01/28/2022
Primary completion :
12/01/2024
Completion :
12/01/2026
BRCA1 • BRCA2 • HRD • BAP1 • RAD51B • BRIP1 • RAD51C • PARP1 • RAD50 • RAD54L • BARD1 • XRCC2 • NBN • RAD54B • XRCC3
|
BRCA1 mutation • ATM mutation • HRD • PALB2 mutation • BAP1 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • BARD1 mutation • HRD + BRCA1 mutation • MRE11A mutation • RAD54L mutation • NBN mutation
|
Zejula (niraparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Massachusetts General Hospital
Recruiting
Last update posted :
12/15/2021
Initiation :
02/12/2020
Primary completion :
12/01/2030
Completion :
12/01/2040
TP53 • BRCA1 • BRCA2 • MSH6 • MLH1 • MSH2 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • EPCAM • NBN • HOXB13 • GEN1
|
BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • PMS2 mutation • NBN mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Se-Hoon Lee
Recruiting
Last update posted :
08/25/2021
Initiation :
08/23/2021
Primary completion :
12/31/2022
Completion :
12/31/2022
BRCA1 • BRCA2 • RAD51 • RAD51B • SLFN11 • RAD51C • BRCA • RAD50 • RAD54L • NBN • RAD52 • RECQL5 • WRN • POU2F3 • RECQL • RECQL4 • RPA1
|
BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • MRE11A mutation • RAD54L mutation • BLM mutation • BRCA mutation • NBN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation
|
Avastin (bevacizumab) • Lynparza (olaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting
Last update posted :
03/03/2021
Initiation :
03/01/2021
Primary completion :
03/01/2024
Completion :
03/01/2027
HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • ARID1A • PBRM1 • CDK12 • RAD51 • BRIP1 • CHEK2 • FANCA • RAD51C • RAD51D • ARID2 • RAD54L • BARD1 • NBN • DRD
|
HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • PBRM1 mutation • BRIP1 mutation • CHEK2 mutation • RAD51C mutation • FANCA mutation • RAD51D mutation • BARD1 mutation • NBN mutation • DRD
|
Zejula (niraparib) • Jemperli (dostarlimab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
Samsung Medical Center
Completed
Last update posted :
02/18/2021
Initiation :
08/01/2016
Primary completion :
01/01/2021
Completion :
01/01/2021
BRCA1 • BRCA2 • ATM • RAD51 • RAD51B • RAD51C • RAD50 • RAD54L • NBN • RAD52 • RECQL5 • WRN • RECQL • RECQL4 • RPA1
|
BRCA2 mutation • BRCA1 mutation • RAD51C mutation • RAD51D mutation • RAD50 mutation • RAD51B mutation • MRE11A mutation • RAD54L mutation • BLM mutation • NBN mutation • WRN mutation • RAD52 mutation • RECQL mutation • RECQL4 mutation • RECQL5 mutation • RPA1 mutation
|
Lynparza (olaparib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)